Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| STATEMENT | OF | CHANGES | IN BEN | NEFICIAL | OWNERS | HIP |
|-----------|----|---------|--------|----------|--------|-----|
|           |    |         |        |          |        |     |

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person*  Marshall Ken W.                  |   |            |            |                                  |   | Aquestive Therapeutics, Inc. [ AQST ] |                 |  |                  |          |   |                 |   | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner                                |   |   |   |            |  |
|--|---|------------|------------|----------------------------------|---|---------------------------------------|-----------------|--|------------------|----------|---|-----------------|---|--|---|---|---|------------|--|
| (Last) (First) (Middle) C/O AQUESTIVE THERAPEUTICS, INC.                   |   |            |            |                                  | 3. Date of Earliest Transaction (Month/Day/Year) 09/18/2019 |                                       |                 |  |                  |          |   |                 | X Officer (give title below) Other (specify below)  SVP, Chief Commercial Officer   |  |   |   |   |            |  |
| (Street)   | 0 TECHNOLOGY DRIVE treet) VARREN NJ 07059 |            |            | 4.1                              | 4. If Amendment, Date of Original Filed (Month/Day/Year)    |                                       |                 |  |                  |          |   | Line            | Individual or Joint/Group Filing (Check Applicable Line)      X Form filed by One Reporting Person     Form filed by More than One Reporting Person |  |   |   |   |            |  |
| (City)   | (S  | •          | (Zip)      | n Davis                          |   | - 6-                                  |                 |  |                  | D:-      |   | -f D            |   | l O  |   |   |   |            |  |
| 1. Title of Security (Instr. 3)  2. Transa Date (Month/D                   |   |            | action     | 2A. Deemed Execution Date,       |   |                                       | Code (Instr. 5) |  |                  | d (A) or | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following                                 |                 |   |  | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership |   |   |            |  |
|  |   |            |            |                                  |   |                                       |                 |  | Code             | v        | Amount  | (A) or<br>(D)   | Price   | Reported<br>Transaction(s)<br>(Instr. 3 and 4)   |   |   |   | (Instr. 4) |  |
| Common Stock   |   |            |            |                                  |   |                                       |                 |  |                  |          | 1,445   |                 |   | T I  | See<br>Footnote <sup>(1)</sup>                      |   |   |            |  |
|  |   | -          | Table II - |                                  |   |                                       |                 |  |                  |          | osed of,  |                 |   | Owned  |   |   | ,                                       |            |  |
| 1. Title of Derivative Conversion or Exercise Price of Derivative Security |   |            | Date,      | ate, Transaction<br>Code (Instr. |   |                                       |                 | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                  |          | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |                 | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)   | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) |   | 10.<br>Ownershi<br>Form:<br>Direct (D)<br>or Indirec<br>(I) (Instr. 4 | Beneficial<br>Ownership<br>t (Instr. 4) |            |  |
|  |   |            |            |                                  | Code  | v                                     | (A)             | (D)  | Date<br>Exercisa |          | Expiration<br>Date  | Title           | Amount<br>or<br>Number<br>of<br>Shares  |  |   |   |   |            |  |
| Non-<br>Qualified<br>Stock<br>Option<br>(right to<br>buy)                  | \$3.49                                    | 09/18/2019 |            |                                  | A   |                                       | 66,000          |  | (2)              |          | 09/18/2029  | Common<br>Stock | 66,000  | \$0  | 66,0  | 00  | D                                       |            |  |

## **Explanation of Responses:**

- 1. Shares held by the Tasro Consulting, LLC 401(k) Plan, Kenneth Marshall Trustee, f/b/o Kenneth Marshall.
- 2. The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

## Remarks:

/s/ Robert Arnold, as Attorney-

09/20/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.